Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 5/20 | 0.36 |
| ▸ | NAAA | Q02083 | 5/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13586315 | 0.93 | SYK (0.39) | NAAASYKAPPFFAR1 | |
| SCHEMBL12823910 | 0.93 | SYK (0.39) | NAAASYKAPPFFAR1 | |
| SCHEMBL12823856 | 0.91 | FEN1 (0.35) | MRGPRX4FPR2ALOX5APFEN1FFAR4 | |
| SCHEMBL12822902 | 0.91 | FEN1 (0.35) | MRGPRX4FPR2ALOX5APFEN1FFAR4 | |
| SCHEMBL13586221 | 0.89 | FFAR4 (0.38) | MRGPRX4FPR2ALOX5APFEN1FFAR4 | |
| SCHEMBL12821314 | 0.89 | FFAR4 (0.38) | MRGPRX4FPR2ALOX5APFEN1FFAR4 | |
| SCHEMBL12994783 | 0.88 | FFAR4 (0.35) | MRGPRX4FPR2ALOX5APFEN1FFAR4 | |
| SCHEMBL12821296 | 0.87 | FEN1 (0.37) | FPR2NAAAALOX5APFEN1FFAR4 | |
| SCHEMBL12822361 | 0.87 | FEN1 (0.37) | FPR2NAAAALOX5APFEN1FFAR4 | |
| SCHEMBL12822782 | 0.86 | ALOX5AP (0.32) | ALOX5APFEN1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2266941-A1 | TRICYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | Chisso Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | MRGPRX4 4652/4885FPR2 2267/4885NAAA 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.